비삼출성 망막 질환 치료제 시장(2026년)

What's New:

The “2026 Nonexudative Retinal Disease Pharmaceuticals Market Report” features new disease estimates and forecasts for complement inhibitors, gene and cellular therapies, and other emerging approaches for treating nonexudative retinal diseases. It examines the US experience with complement inhibitors and their continued geographic expansion, while tracking updated companies and clinical-stage drug-development programs, including those being submitted for regulatory approval. The report also reflects the latest development stages of promising drug-delivery platforms.

Description:

The “2026 Nonexudative Retinal Disease Pharmaceuticals Market Report” provides a comprehensive analysis of current and emerging therapies for geographic atrophy, dry AMD, and other nonexudative retinal diseases. It examines complement inhibitors, gene therapies, sustained-release technologies, antioxidants, and other evolving treatment approaches, along with key market trends, patient economics, reimbursement dynamics, and five-year growth forecasts.

The report also features detailed unit and revenue projections, market share estimates by product category, and profiles of 19 leading competitors, including insights into their strategies, pipelines, and future outlooks.

Pricing:

2 licensing types are available for this report:

• The price of the single-user license is $5,700.
• The price of the enterprise license is $8,550 (includes supplemental Excel file with all the tables and figures in the report, and report summary slides).

Both licenses include an electronic PDF. Printed copies may be purchased for an additional $250.

SINGLE USER LICENSE

• The Single User License allows for the use of a report by a single user within one corporate location.
• The report paper copy may not be reproduced (additional paper copies available for purchase).
• Report PDF copy can not be copied (if purchased) and must remain on one computer (not a company server).
• Only a single copy of the publication may be printed for internal use.
• Users may include information in the report in presentations and internal reports by providing full copyright credit to Market Scope.
• Users may not share the report (or any information contained therein) with any other person or persons outside the corporate location for which the report is purchased.

ENTERPRISE LICENSE

• The Enterprise License allows for the use of a report by unlimited users within the purchasing organization.
• Purchasing organization shall have the right to share the report with third parties. (investors, consultants, etc.) from time to time under the global license agreement, provided that such third parties have a confidentiality agreement with the purchasing organization and agree to be bound by the terms of the global license agreement.
• Employees of the purchasing organization can include information given in the report in presentations and internal reports by providing full copyright credit to Market Scope.
• Purchase price includes a printable PDF file of the report (purchasing organization may print multiple copies for use within the organization).
• Purchase price includes a supplemental Excel file containing all the tables and figures included in the purchased report.
• Pay by credit card or by invoice.

Table of Contents

The “2026 Nonexudative Retinal Disease Pharmaceuticals Market Report” provides a clear, data-driven view of the evolving treatment landscape for geographic atrophy, dry AMD, and other nonexudative retinal diseases.

Coverage highlights include:

• Disease overview and risk factors: discussion of nonexudative retinal diseases, their causes, disease progression, and links to systemic health and lifestyle.
• Diagnosis and treatment landscape: examination of diagnostic technologies, patient management trends, and the growing role of pharmaceutical intervention.
• Global retinal care environment: overview of global retinal care delivery, patient access, specialist distribution, and treatment adoption trends.
• Current therapies in the market: analysis of approved pharmaceuticals and biologics, including market penetration, pricing dynamics, and competitive positioning.
• Development pipeline: review of investigational agents in development—complement inhibitors, gene therapies, sustained-release devices, and more—shaping the next generation of care.
• Company profiles and preclinical activity: profiles of companies developing or marketing therapies for nonexudative retinal disease, plus a listing of additional firms with preclinical programs.